Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis.

Strohbehn GW, Tokaz MC, Shin DS, Jalal S, Tavalire HF, Gyori DJ, Moeller JA, Bazzell BG, Kelley MJ, Fendrick AM, Elliott DA, Ramnath N, Hofer TP, Bryant AK. Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis. JCO oncology practice. 2026 Jun 18; OP2501241, DOI: 10.1200/OP-25-01241.

Related HSR&D Project(s)

• CDA 22-190 – Democratically Designed Optimal Dosing Regimens To Combat Overuse

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

PURPOSE: Pemetrexed remains part of guideline-recommended maintenance pemetrexed/pembrolizumab in advanced/metastatic non-oncogene-driven nonsquamous non-small cell lung cancer (NSCLC). Whether pemetrexed contributes to the combination''s survival benefit is unknown. In this propensity-weighted analysis of US Veterans Affairs data, we compared real-world effectiveness and safety of maintenance pemetrexed/pembrolizumab versus maintenance pembrolizumab alone and estimated US government payer spending on maintenance pemetrexed. METHODS: We identified Veterans who received four cycles of carboplatin/cisplatin, pemetrexed, and pembrolizumab followed by at least one dose of maintenance pemetrexed/pembrolizumab or pembrolizumab. A propensity-weighted Cox model was used to adjust for baseline between-group differences using inverse probability of treatment weights. The primary effectiveness outcome was overall survival (OS; time from first maintenance dose to death). The primary financial outcome was the estimated spending on maintenance pemetrexed across VA, Medicare Part B, and Medicaid (2017-2022). RESULTS: The real-world outcomes cohort included 622 patients (473 pemetrexed/pembrolizumab; 149 pembrolizumab alone). After propensity weighting, pemetrexed was not associated with improved OS (adjusted hazard ratio [aHR] pemetrexed/pembrolizumab < i > v < /i > pembrolizumab, 1.06 [95% CI, 0.83 to 1.36, < i > P < /i > = .62]) but was associated with higher toxicity risk (grade ≥3 acute kidney injury [aHR 3.35, 95% CI, 1.08 to 10.41, < i > P < /i > = .04]; neutropenia [aHR 2.86, 95% CI, 1.44 to 3.05; < i > P < /i > = .004]; anemia [aHR 1.65, 95% CI, 1.11 to 2.47, < i > P < /i > = .014]). Findings were robust to sensitivity analysis in which patients who crossed over from pembrolizumab to pemetrexed/pembrolizumab were excluded. Estimated government payer spending on maintenance pemetrexed from 2017 to 2022 totaled $1.588 billion (2024 USD). CONCLUSION: Adding pemetrexed to maintenance pembrolizumab was not associated with improved survival but was associated with increased toxicity. Reassessing legacy chemotherapy components may improve the safety and cost-effectiveness of cancer care < b > . < /b > Prospective evaluation of maintenance pemetrexed''s incremental benefit in NSCLC in the immunotherapy era is needed.